Walter & Keenan Wealth Management’s AbbVie ABBV Stock Holding History

Walter & Keenan Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.01M	Sell	23,876 -93	-0.4%	-$20K	1.49%	19
2026 Q1	$5.21M	Sell	23,969 -718	-3%	-$159K	1.47%	21
2025 Q4	$5.64M	Buy	24,687 +25	+0.1%	+$5.7K	1.51%	19
2025 Q3	$5.71M	Sell	24,662 -1,068	-4%	-$217K	1.58%	19
2025 Q2	$4.78M	Sell	25,730 -1,327	-5%	-$247K	1.39%	22
2025 Q1	$5.67M	Buy	27,057 +241	+0.9%	+$46.9K	1.71%	17
2024 Q4	$4.77M	Sell	26,816 -217	-0.8%	-$39.9K	1.44%	21
2024 Q3	$5.34M	Buy	27,033 +21	+0.1%	+$3.92K	1.62%	16
2024 Q2	$4.63M	Sell	27,012 -270	-1%	-$44.7K	1.48%	17
2024 Q1	$4.97M	Sell	27,282 -1,399	-5%	-$241K	1.63%	17
2023 Q4	$4.44M	Buy	28,681 +70	+0.2%	+$10.2K	1.59%	16
2023 Q3	$4.26M	Sell	28,611 -541	-2%	-$79.4K	1.66%	15
2023 Q2	$3.93M	Sell	29,152 -582	-2%	-$85.3K	1.44%	19
2023 Q1	$4.74M	Sell	29,734 -1,295	-4%	-$198K	1.8%	13
2022 Q4	$5.01M	Buy	31,029 +807	+3%	+$124K	1.97%	12
2022 Q3	$4.06M	Buy	30,222 +589	+2%	+$84.5K	1.72%	13
2022 Q2	$4.54M	Sell	29,633 -439	-1%	-$67.1K	1.79%	14
2022 Q1	$4.88M	Hold	30,072	–	–	1.65%	17
2021 Q4	$4.07M	Sell	30,072 -99	-0.3%	-$11.7K	1.32%	23
2021 Q3	$3.25M	Sell	30,171 -118	-0.4%	-$13.5K	1.1%	27
2021 Q2	$3.41M	Sell	30,289 -240	-0.8%	-$27K	1.18%	25
2021 Q1	$3.3M	Sell	30,529 -340	-1%	-$36.4K	1.17%	27
2020 Q4	$3.31M	Sell	30,869 -393	-1%	-$37.8K	1.2%	25
2020 Q3	$2.74M	Buy	31,262 +1,216	+4%	+$114K	1.09%	30
2020 Q2	$2.95M	Buy	30,046 +25,016	+497%	+$2.2M	1.2%	28
2020 Q1	$369K	Sell	5,030 -23,537	-82%	-$2M	0.15%	77
2019 Q4	$2.53M	Buy	28,567 +101	+0.4%	+$8.38K	0.97%	35
2019 Q3	$2.15M	Buy	28,466 +1,696	+6%	+$116K	0.82%	39
2019 Q2	$1.95M	Hold	26,770	–	–	0.86%	35
2019 Q1	$2.16M	Buy	26,770 +449	+2%	+$36.7K	0.95%	34
2018 Q4	$2.43M	Hold	26,321	–	–	1.09%	29
2018 Q3	$2.49K	Buy	26,321 +555	+2%	+$52.6K	0.75%	32
2018 Q2	$2.39M	Sell	25,766 -6,750	-21%	-$659K	1.03%	32
2018 Q1	$3.08M	Sell	32,516 -2,500	-7%	-$275K	1.33%	22
2017 Q4	$3.39M	Hold	35,016	–	–	1.42%	20
2017 Q3	$3.11M	Buy	35,016 +650	+2%	+$49.5K	1.44%	19
2017 Q2	$2.49M	Hold	34,366	–	–	1.25%	23
2017 Q1	$2.24M	Buy	34,366 +400	+1%	+$25.1K	1.16%	27
2016 Q4	$2.13M	Buy	33,966 +250	+0.7%	+$15.3K	1.13%	28
2016 Q3	$2.13M	Sell	33,716 -2,236	-6%	-$145K	1.17%	27
2016 Q2	$2.23M	Buy	35,952 +1,902	+6%	+$116K	1.24%	26
2016 Q1	$1.95M	Buy	34,050 +1,750	+5%	+$97.5K	1.11%	30
2015 Q4	$1.91M	Buy	32,300 +1,300	+4%	+$74.9K	1.11%	30
2015 Q3	$1.69M	Buy	31,000 +2,200	+8%	+$143K	1.04%	32
2015 Q2	$1.94M	Hold	28,800	–	–	1.12%	30
2015 Q1	$1.69M	Buy	28,800 +7,500	+35%	+$453K	0.95%	39
2014 Q4	$1.39M	Hold	21,300	–	–	0.79%	47
2014 Q3	$1.23M	Hold	21,300	–	–	0.72%	49
2014 Q2	$1.2M	Buy	21,300 +1,000	+5%	+$52.5K	0.63%	54
2014 Q1	$1.04M	Buy	+20,300	New	+$1.03M	0.57%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Walter & Keenan Wealth Management's ABBV Position: Q2 2026 in Review

Walter & Keenan Wealth Management reduced its AbbVie (ABBV) stake by 0.39% in Q2 2026, selling an estimated $20K and leaving 23,876 shares worth $6.01M. The position accounts for 1.49% of the portfolio, ranked #19.

Walter & Keenan Wealth Management first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Walter & Keenan Wealth Management held 23,876 shares of AbbVie worth $6.01M as of Q2 2026.
Walter & Keenan Wealth Management sold 93 AbbVie shares in Q2 2026, an estimated $20K.
AbbVie made up 1.49% of Walter & Keenan Wealth Management's portfolio in Q2 2026, its #19 holding.
Walter & Keenan Wealth Management first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Walter & Keenan Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.